New Chairman Brings “Wealth of Experience” to Pioneering Biotech Firm Simon Sturge, Executive Vice President of Business, Operations and Strategy at Merck Healthcare, is today confirmed as the new Chairman of Nemesis Bioscience, the British biotechnology business tackling antibiotic resistance with breakthrough technologies. This is a very significant appointment for Nemesis given Mr Sturge’s extensive career in senior roles across the pharmaceutical and biotech sectors. He founded RiboTargets; served as

PHOTO:  From Left: Prof Conrad Lichtenstein (Nemesis CSO), Dr Frank Massam (Nemesis CEO), Dr Takeshi Shiota (Shionogi SVP, Pharmaceutical Research Division) and Dr Kai Stoeber

Nemesis Bioscience today announced the appointment of Dr Mark McCamish as Scientific Advisor for the development of its suite of Bacterial Cybergenetics© technologies. These include

Nemesis Bioscience today announced the successful completion of its latest funding round, bringing total seed funds raised to more than £700,000, and the commencement of

Nemesis Bioscience today announced the appointment of Dr Alastair Riddell as non-executive Chairman. The appointment is effective from the 1st July and will bring Alastair’s

Nemesis Bioscience has beaten tough competition from across the country to win a place to showcase its product at the UK’s largest innovation show in

Nemesis Bioscience Ltd (Cambridge, UK) announced today that it has received a funding award from the UK’s innovation agency, Innovate UK. The Smart Award will

Nemesis Bioscience Ltd has raised £300,000 in seed funding from Angel investors and from Finance Wales to extend the application of its proprietary biological therapeutics

Nemesis Bioscience Ltd (Cambridge, UK) announced today that it has been awarded an Entrepreneurship Award by King’s College, Cambridge. The King’s College judges, who include